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Abstract
Background: Several studies suggest that cardiovascular risk factors comprising the metabolic syndrome have larger effects
on the development of cardiovascular disease in women than in men. A recent study in self-reported healthy subjects
demonstrated a marked gender difference in endothelial dysfunction that may be an important precursor of manifest
cardiovascular disease. The aim of the present study was to determine whether the association between endothelial
function and cardiovascular risk factors is different in self-reported healthy women compared to self-reported healthy men.
Methods and Results: Associations between endothelial function (flow mediated dilation, FMD, of the brachial artery
measured by ultrasound), anthropometric variables, peak oxygen uptake (VO2peak), blood pressure, serum lipids, blood
glucose and a questionnaire on general health and lifestyle including smoking status were studied by logistic and linear
regression in 2 528 women and 2 211 men aged 20–89 years, free from self-reported cardiovascular disease. In women with
hyperglycemia, endothelial dysfunction (FMD #0%) occurred twice as frequently as in male counterparts. The presence of
the metabolic syndrome, high blood pressure and low VO2peak increased the prevalence of endothelial dysfunction more in
women than in men.
Conclusion: Endothelial dysfunction is more strongly associated with cardiovascular risk factors in self-reported healthy
women than in self-reported healthy men. This finding could explain why the metabolic syndrome, and especially
hyperglycemia, is associated with higher cardiovascular risk and a worse prognosis in women.
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Introduction
Endothelial dysfunction (ED) predicts vascular events in subjects
with and without established cardiovascular disease (CVD) [1,2],
and is associated with risk factors for atherosclerosis [3,4,5,6]. A
recent survey of self-reported healthy respondents from the
HUNT3 Fitness study [7] demonstrated that women have better
endothelial function than men in all age groups up to 65–70 years
of age. This gender difference corresponds to the age-related
incidence of CVD.
The metabolic syndrome increases the risk of cardiovascular
disease and worsens the prognosis more in women than in men
[8,9,10,11,12]. Furthermore, ED seems to potentiate the negative
effect of the metabolic syndrome on mortality and cardiovascular
events in women [13,14]. These observations are consistent with
the notion that endothelial function may be a pivotal factor
explaining gender differences in CVD. The aim of the present
study was to determine whether the association between
endothelial function and cardiovascular risk factors is different
in self-reported healthy women compared to self-reported healthy
men.
Study Population and Methods
Inclusion and exclusion
Associations between endothelial function and cardiovascular
risk factors were studied in a subset of the HUNT3 health survey.
HUNT3 covered 52% of the population in Nord-Trøndelag
County, which is considered a close average of the general
Norwegian population. The selection and characteristics of 4 739
adult respondents from the HUNT3 Fitness study and their age
and gender distribution of flow mediated dilation (FMD) was
recently reported [7]. Briefly, the respondents completed health-
related questionnaires including physical activity habits, and
underwent measurements of endothelial function (flow mediated
dilation; FMD), peak oxygen uptake (VO2peak), and a brief clinical
examination (7). Inclusion criteria were participation in the
HUNT3 main study and informed consent to participate in the
HUNT3 Fitness Study. Exclusion criteria were self-reported
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e101371
episodes of obstructive breathing or dyspnea for the past 12
months, present or former asthma, chronic obstructive pulmonary
disease, sarcoidosis, cancer, and established CVD, including
cerebral and peripheral arterial disease, angina pectoris and
previous myocardial infarction, contraindications towards physical
activity, and use of antihypertensive or vasoactive medication
known to influence endothelial function. Respondents with cardiac
arrhythmias during testing were excluded.
Of 30 165 participants who were ‘‘self-reported healthy’’
according to these criteria, 18 608 were randomly invited to the
Fitness Study [7]. Out of the 5 636 that were included at
attendance, 4739 (2 528 women and 2 211 men) were willing to
participate and completed endothelial function testing, comprising
our study population. A flowchart of inclusion, and characteristics
of selection and the study population, including risk profile, are
presented in our previous publication [7].
Approvals
The Regional Ethics Committee, the Norwegian Data Inspec-
torate, and the Ministry of Health and Care Services approved of
the HUNT3 Fitness study. The Study Protocol conformed to the
Helsinki declaration, and written informed consent was obtained
from all participants.
Endothelial function test
FMD was assessed in the left brachial artery by a 3-point
echocardiography system (Vivid i, GE Healthcare, USA) with a
high-resolution 12 MHz array transducer. A blood pressure cuff
was placed on the forearm [15,16] and the participants were in
supine position in a quiet and dark room. Blood flow was
estimated by pulsed Doppler velocity signals. The brachial artery
was imaged at baseline after ten minutes of supine rest, and 60
seconds after cuff deflation following 5 minutes of arterial
occlusion at 250 mm Hg. Arterial diameter was measured from
intima to intima at the peak of the R-wave to avoid confounding of
cyclic changes. The mean of three consecutive diameter measure-
ments was recorded.
FMD was defined as percent change in vessel diameter,
calculated as (post occlusion diameter minus baseline diameter)
divided by baseline diameter. ED was defined as FMD #0%.
Shear rate yielded the same patterns for age and gender (7),
therefore only unadjusted values were included in the present
analyses. Interobserver analysis of recordings gave a mean
difference ranging from 21.236 (95% CI: 25.377 to 2.904) to
2.250 (95% CI: 21.348 to 5.848) using the Bland–Altman plot,
with Pitman’s Test of difference in variance ranging from r= 0.008
(n= 81, p= 0.942) to r =20.846 (n = 82, p= 0.000).
All subjects received written information in advance and were
asked to fast and refrain from coffee and tobacco the last four
hours before test, but this was not achieved in all respondents since
recordings were taken throughout the entire day. Still, there was
no difference in FMD between fasting and non-fasting subjects. As
detailed below, the criterion for hyperglycaemia was adjusted to
account for suboptimal fasting conditions.
Clinical measures
Resting heart rate was recorded as the lowest heart rate during
supine rest for 10 minutes. Blood pressure was measured (Critikon
Dinamap 845XT, GE Medical Systems, USA) according to
guidelines [17]. Height and weight were measured to the nearest
centimeter (cm) and kilogram on a combined scale (Model DS-
102, Arctic Heating AS, Norway), and body mass index (BMI) was
calculated. Waist circumference was measured to the nearest cm at
the height of the umbilicus, and limits between normal waistline
and overweight set according to the definition for the metabolic
syndrome [18], as referred below. For BMI, overweight was
defined as BMI 25 kg/m2–30 kg/m2 and obesity as BMI.30 kg/
m2. All blood samples were analyzed by photometric methods
Figure 1. Flow-mediated dilation with number of risk factors present. Mean flow mediated dilation adjusted for age and its dependence on
risk factors included in the definition of the metabolic syndrome (waist obesity, hypertension, hyperglycemia, low HDL, and high trigycerides) are
shown separately for women and men. Vertical lines indicate 95% confidence intervals.
doi:10.1371/journal.pone.0101371.g001
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(Architect ci8200, Abbott Laboratories, IL, USA). VO2peak was
measured by ergospirometry during treadmill running [19] and
physical activity index calculated as described by Aspenes et al
[20].
CVD risk factors
The following cardiovascular risk factors were assessed: Systolic
and diastolic blood pressure, waist circumference, body mass
index, total cholesterol, high-density lipoprotein (HDL) cholester-
ol, blood glucose, serum triglycerides, fitness (VO2peak), physical
activity index [20], smoking (yes or no), and the cluster of risk
factors comprising the metabolic syndrome. LDL cholesterol was
not measured in HUNT3 health survey. The risk profile was
calculated according to ESC Score for population at low
cardiovascular risk based on the ratio between total and HDL
cholesterol [21].
The metabolic syndrome was defined according to current
recommendations [18], as the presence of at least three of the
following; elevated waist circumference ($94 cm in men, $80 cm
in women), serum triglycerides $1.7 mmol/L, low HDL-choles-
terol (,1.0 mmol/L in men, ,1.3 mmol/L in women), elevated
blood pressure (systolic blood pressure $130 and/or diastolic
blood pressure $85 mm Hg) and elevated fasting glucose. To
account for blood sampling less than four hours of fasting in the
majority of participants, the glucose criterion was changed from $
5.6 mmol/L, to $7.8 mmol/L, corresponding to the impaired
glucose tolerance criterion [22].
Statistical analysis
Since our previously published analyses of the Fitness Study
cohort demonstrated consistent age and gender differences in
FMD [7], data from women and men were analyzed separately,
and regression analysis repeated with and without adjustment for
age. Means with 95% confidence intervals were calculated for
baseline brachial artery diameter and FMD. Baseline character-
istics were compared between groups using a 2-tailed independent
t-test for continuous variables. Fisher’s z-transform method was
used to compare correlation coefficients between the genders.
Associations between FMD, ED and risk factors were analyzed by
logistic regression and multiple linear regression. Trends across
ordered groups were identified by test for linearity, by nonpara-
metric equality-of-medians test, and by the Wilcoxon rank-sum
test corrected for ties. Results are reported from nonparametric
analyses unless else is specified. Cases with missing values were
excluded from multivariate analyses. Regression analyses were
adjusted for smoking status. SPSS software version 17 was used for
all statistical analyses.
Results
Metabolic syndrome and FMD
In women, FMD was lower (p,0.001) and the prevalence of
ED was higher (p = 0.013) with the presence of the metabolic
syndrome (Table 1, 2). There was also a positive association for the
prevalence of ED (p= 0.009), and a linear negative association for
FMD (p,0.001) respectively, with the number of metabolic
syndrome components present (Fig. 1). In men, there was only a
trend for association between FMD and the number of metabolic
syndrome components (p = 0.10). In women with the metabolic
syndrome, its presence could explain 25% of the variance of FMD
(effect of 3 versus 0 risk factors; r = 0.52, p,0.001).
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Blood glucose
Regardless of other risk factors, FMD in women with
hyperglycemia was lower (p = 0.005) and prevalence of ED
(p= 0.004) higher than in women with normoglycaemia. This
was not observed in men (Table 2, Fig. 2; differences in men with
hyperglycemia vs normoglycaemia: FMD, p= 0.65 and ED,
p= 0.47). Odds ratios for ED in subjects with hyperglycemia were
2.78 (95% CI: 2.57–2.99) in women and 1.20 (1.12–1.28) in men
(Table 3). For both genders, the prevalence of ED in hypergly-
cemic subjects was markedly higher than in subjects with the
Figure 2. Gender difference in flow-meditated dilation with glycemic status. Mean flow-mediated dilation adjusted for age and its
dependence on glycemic status are shown separately for women and men. Vertical lines indicate 95% confidence intervals. Difference between
normo-and hyperglycemic women, p= 0.003, men p= 0.91.
doi:10.1371/journal.pone.0101371.g002
Table 3. Odds ratios for endothelial dysfunction, single predictorsa.
Both genders Women Men
OR (95% CI) OR (95% CI) OR (95% CI)
Met Syn 1.20 (1.16–1.23) 1.34 (1.29–1.39) 1.07 (1.03–1.11)
Unfit 1.31 (1.28–1.34) 1.54 (1.46–1.55) 1.12 (1.09–1.16)
Smoking 1.29 (1.26–1.32) 1.44 (1.40–1.49) 1.13 (1.09–1.17)
High blood pressure 1.30 (1.28–1.33) 1.33 (1.30–1.36) 1.28 (1.25–1.31)
Stage 1 hypertension 1.45 (1.41–1.50) 1.57 (1.51–1.64) 1.31 (1.26–1.36)
Stage 2 hypertension 1.82 (1.26–2.08) 2.40 (2.25–2.56) 1.28 (1.20–1.38)
High blood pressure+smokingb 1.65 (1.57–1.74) 2.10 (1.95–2.25) 1.35 (1.26–1.45)
Hyperglycemia 1.69 (1.61–1.78) 2.78 (2.57–2.99) 1.20 (1.12–1.28)
Low HDL 0.88 (0.85–0.90) 0.95 (0.92–0.99) 0.78 (0.74–0.82)
Low VO2 peak 1.99 (1.92–2.06) 2.69 (2.56–2.83) 1.52 (1.45–1.59)
Low VO2 peak+high blood
pressure+smokingc
2.15 (2.00–2.32) 2.68 (2.41–2.97) 1.76 (1.59–1.95)
All listed predictors are significant for endothelial dysfunction (p,0.05). OR:odds ratio; CI: 95% confidence interval; MetSyn: metabolic syndrome; unfit: VO2 peak adjusted
for body weight below median for study population; high blood pressure: systolic blood pressure $130 and/or diastolic blood pressure $85 mmHg (millimeters
mercury); Stage 1 hypertension: Systolic blood pressure $140 and ,160 mmHg or diastolic blood pressure $90 and ,100 mm Hg; Stage 2 hypertension: Systolic
blood pressure $160 and ,180 mmHg or diastolic blood pressure $100 and ,110 mm Hg; low HDL: high-density lipoprotein cholesterol ,1.0 mmol/L in men and ,
1.3 mmol/L in women; low VO2 max: lowest gender specific quartile compared to the highest adjusted for body weight.
ainteraction variables included in term ‘‘single predictor’’;
binteraction variable between high blood pressure and smoking;
cinteraction variable between low VO2peak, high blood pressure and smoking. Values are adjusted for age.
doi:10.1371/journal.pone.0101371.t003
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metabolic syndrome (Table 2, Table 3). In women with the
metabolic syndrome, there was a marked difference in FMD (p,
0.001) and prevalence of ED (p= 0.004) between those with
hyperglycemia and those with normoglycaemia. In hypertensive
women, but not in hypertensive men, FMD was reduced in
subjects with concomitant hyperglycemia, compared to hyperten-
sive subjects with normoglycaemia (p= 0.02, Table 4).
Blood pressure
In women, the correlation between FMD and systolic blood
pressure (SBP) was 20.13, and the regression coefficient 20.11
(p,0.001); in men the correlation was 20.07 and the regression
coefficient 20.09 (p,0.05); difference: z =22.06, p = 0.02. Odds
ratios for ED in subjects with hypertension were higher in women
than in men (Table 3), and markedly so in subjects with stage II
hypertension (systolic blood pressure $160 and ,180 mm Hg or
diastolic blood pressure $100 and ,110 mm Hg) with an odds
ratio of 2.40 (95% CI: 2.25–2.56) in women and 1.28 (1.20–1.38)
in men. In the range of systolic blood pressures from 100 mmHg
to 165 mmHg, FMD declined with increasing blood pressures (p,
0.001, Fig. 3) in women, but not in men. In the same range, the
prevalence of ED was also higher with increasing blood pressure
(p,0.001) in women, but not in men (Table 1).
Other risk factors
The correlation between fitness (VO2 peak) and FMD was 0.124
(p,0.001) in women and 0.053 (p = 0.016) in men (difference:
z = 2.44, p = 0.007). Odds ratios for ED in subjects with low fitness
were 1.54 (95% CI: 1.46–1.55) in women, and 1.12 (1.09–1.16) in
men (Table 3).
Odds ratio for ED was higher in female smokers than in male
smokers (1.44, 95% CI: 1.40–1.49 vs. 1.13, 95% CI: 1.09–1.17).
When adjusting regression models for systolic blood pressure and
VO2 peak, smoking was no longer associated with low FMD in
men, but persisted in women. More detailed analyses of the effect
on endothelial function by smoking habits will be reported in a
separate study.
Overweight and obesity had no impact on FMD or the
prevalence of ED in either gender. Significant predictors for ED
are listed in Table 3.
Discussion
The main finding of the current study was that hyperglycemia,
high blood pressure, low fitness and a cluster of cardiovascular risk
factors comprising the metabolic syndrome are more strongly
associated with reduced flow-mediated vasodilation (FMD) and
endothelial dysfunction (ED) in women than in men.
Figure 3. Flow-mediated dilation in normotension and hypertension class I and II. Mean flow-mediated dilation adjusted for age and its
dependence with blood pressure groups are shown separately for women and men. Vertical lines indicate 95% confidence intervals.
doi:10.1371/journal.pone.0101371.g003
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Metabolic factors
It has previously been shown that mortality from CVD is higher
in subjects with the metabolic syndrome [23], and that this
association is stronger in women than in men [13,23]. It has also
been suggested that hyperglycemia per se, more than the
metabolic syndrome as an entity, predicts the prognosis and
outcome in CVD [7,18,24,25,26], and that young women are
especially prone to the negative effects of both [27]. The present
study shows that FMD was lower and prevalence of ED was higher
in women with hyperglycemia. This was not the case in male
counterparts. In women with the metabolic syndrome, there was
also a marked difference in FMD and the prevalence of ED
between those with hyperglycemia and those with normoglycae-
mia. Estrogens have been suggested as a key mechanism of
women’s lower relative cardiovascular disease risk; possibly by
mobilizing endothelial progenitor cells from the bone marrow and
protection from apoptosis [28]; insulin resistance has been
negatively correlated with the number of endothelial progenitor
cells [29]. Increased formation of advanced glycation end products
(AGE) is regarded as one of the main mechanisms of vascular
damage in patients with diabetes [30]. These products affect cell
function by binding to their receptor [31], thereby inducing
endothelial dysfunction. Women usually have lower incidence of
heart disease prior to menopause, suggesting that estrogen may
protect towards endothelial dysfunction and heart disease. Some
studies have shown a gender difference, with healthy young
women presenting higher plasma levels of AGE compared to their
male counterparts [32,33]. Another study has shown that
estrogens inhibit the synthesis of AGE in vaginal epithelial tissues
of postmenopausal women [34]. Thus, the role of estrogen
regulating AGE signaling with regard to gender differences
remains unclear [35].
It may also be that women have to undergo a greater metabolic
deterioration than men before insulin resistance, impaired
regulation of blood glucose [30], and endothelial dysfunction
ensue. Alternatively there may be a gender difference in
endothelial expression of specific genes when exposed to hyper-
glycemia [31]. Our findings support the notion that endothelial
dysfunction is an important mechanism of gender-specific effects
on CVD in patients with the metabolic syndrome, hyperglycemia
or diabetes mellitus. Furthermore, the metabolic syndrome used as
an entity may mask important differences in the sensitivity to
specific risk factors, especially hyperglycemia, in assessing health
and mortality [24,25,32].
We observed a trend for association between reduced FMD and
increasing number of metabolic syndrome risk factors also in men,
but the association did not reach the level of significance (Figure 1).
This finding may be due to exclusion of participants with more
than three risk factors because of clinically manifest CVD or drug
treatment of hypertension, thereby underestimating the associa-
tion between the metabolic syndrome and endothelial dysfunction.
However, this may also apply to women with five vs. four risk
factors, underestimating the association in women as well.
Hypertension
The present study is the first to demonstrate a linear decrease in
FMD with increasing systolic blood pressure in self-reported
healthy women and with stronger association in women than in
men. The prevalence of ED was higher with increasing blood
pressure only in women. The strong association between
hypertension and CVD mortality and morbidity is well known
[33,34,35], but there is a lack of knowledge regarding gender-
specific effects of hypertension. Our results suggest that hyperten-
sion is an important determinant of endothelial function in both
genders, and that it may have a larger impact in women.
Hypertension is strongly associated with increased mortality from
ischemic heart disease in patients with type 2 diabetes [36,37],
especially in women [38]. As illustrated in Table 4, our findings
suggest that hyperglycemia negatively affects endothelial function
in hypertensive subjects.
Fitness and obesity
The correlation between FMD and VO2peak was small, though
significant, and larger in women than in men; the age-adjusted
odds ratio for fitness was three times higher with FMD in the
lowest quartile compared to the highest in women but not in men.
Thus, low fitness may affect endothelial function more negatively
in women than in men. These findings concur with previously
reported protective associations of exercise with CVD and
mortality [23,39,40]; and with recent studies demonstrating larger
effects in women than in men [39,41]. In contrast, we found that
overweight and obesity had no impact on FMD or the prevalence
of ED in either gender. In women, obesity had a negative effect on
FMD only in the presence of the metabolic syndrome. Therefore,
obesity is not included in Table 3 as a significant predictor.
Although we only measured body weight and waist circumference,
these results suggest that isolated overweight and obesity are not
likely to be independent risk factors for CVD via their effects on
endothelial function. This is in contrast with previous findings
suggesting an association between these factors and increased
CVD mortality and morbidity [39,42], especially in middle-aged
women [43,44,45,46].
Limitations
The Fitness Study was part of an ambulatory health survey with
a large number of participants who came for examinations at all
times of the day, some directly from work. Although pre-circulated
information asked them to be fasting, they were allowed a snack
while waiting. As a result, 75% reported food intake less than 4
hours before testing. Lacking a standard cut-off for this situation,
we used the criterion for impaired glucose tolerance of $
7.8 mmol/L two hours after an oral glucose tolerance test for all
participants. This cut-off is conservative and may have underes-
timated the number with the metabolic syndrome. The question-
naire data on oral contraceptives and hormone replacement was
self-reported and not sufficiently detailed to be used for statistical
adjustments.
Conclusion
In self-reported healthy subjects, the reduction in endothelial
function in women was more strongly associated with hypergly-
cemia, hypertension, low fitness and the metabolic syndrome than
in men. This gender difference in endothelial function may explain
why the metabolic syndrome, and especially hyperglycemia, is
associated with higher cardiovascular risk and worse prognosis in
women.
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